240 related articles for article (PubMed ID: 22143518)
1. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G
Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518
[TBL] [Abstract][Full Text] [Related]
2. Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease.
Almeida DV; Converse PJ; Li SY; Tyagi S; Nuermberger EL; Grosset JH
PLoS Negl Trop Dis; 2013; 7(2):e2085. PubMed ID: 23469308
[TBL] [Abstract][Full Text] [Related]
3. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
[TBL] [Abstract][Full Text] [Related]
4. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.
Almeida D; Converse PJ; Ahmad Z; Dooley KE; Nuermberger EL; Grosset JH
PLoS Negl Trop Dis; 2011 Jan; 5(1):e933. PubMed ID: 21245920
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease.
Converse PJ; Tyagi S; Xing Y; Li SY; Kishi Y; Adamson J; Nuermberger EL; Grosset JH
PLoS Negl Trop Dis; 2015; 9(6):e0003823. PubMed ID: 26042792
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice.
Dega H; Bentoucha A; Robert J; Jarlier V; Grosset J
Antimicrob Agents Chemother; 2002 Oct; 46(10):3193-6. PubMed ID: 12234844
[TBL] [Abstract][Full Text] [Related]
7. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.
Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239
[TBL] [Abstract][Full Text] [Related]
8. Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.
Zhang T; Li SY; Converse PJ; Almeida DV; Grosset JH; Nuermberger EL
Antimicrob Agents Chemother; 2011 Jan; 55(1):56-61. PubMed ID: 21078940
[TBL] [Abstract][Full Text] [Related]
9. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?
Ruf MT; Chauty A; Adeye A; Ardant MF; Koussemou H; Johnson RC; Pluschke G
PLoS Negl Trop Dis; 2011 Aug; 5(8):e1252. PubMed ID: 21829740
[TBL] [Abstract][Full Text] [Related]
10. Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease.
Sarfo FS; Converse PJ; Almeida DV; Zhang J; Robinson C; Wansbrough-Jones M; Grosset JH
PLoS Negl Trop Dis; 2013; 7(3):e2101. PubMed ID: 23516649
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
Ji B; Lefrançois S; Robert J; Chauffour A; Truffot C; Jarlier V
Antimicrob Agents Chemother; 2006 Jun; 50(6):1921-6. PubMed ID: 16723546
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection.
Martins TG; Trigo G; Fraga AG; Gama JB; Longatto-Filho A; Saraiva M; Silva MT; Castro AG; Pedrosa J
PLoS Negl Trop Dis; 2012; 6(11):e1925. PubMed ID: 23209864
[TBL] [Abstract][Full Text] [Related]
13. Impacts of dosing frequency of the combination rifampin-streptomycin on its bactericidal and sterilizing activities against Mycobacterium ulcerans in mice.
Ji B; Chauffour A; Aubry A; Robert J; Ibrahim M; Jarlier V
Antimicrob Agents Chemother; 2009 Jul; 53(7):2955-9. PubMed ID: 19364857
[TBL] [Abstract][Full Text] [Related]
14. Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.
Almeida DV; Omansen TF; Li SY; Lee J; Grosset JH; Converse PJ; Nuermberger EL
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559131
[TBL] [Abstract][Full Text] [Related]
15. Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin.
Lefrançois S; Robert J; Chauffour A; Ji B; Jarlier V
Antimicrob Agents Chemother; 2007 Feb; 51(2):645-50. PubMed ID: 17101676
[TBL] [Abstract][Full Text] [Related]
16. Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions.
Schütte D; Umboock A; Pluschke G
Br J Dermatol; 2009 Feb; 160(2):273-83. PubMed ID: 19016694
[TBL] [Abstract][Full Text] [Related]
17. Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection.
Martins TG; Gama JB; Fraga AG; Saraiva M; Silva MT; Castro AG; Pedrosa J
PLoS One; 2012; 7(2):e32740. PubMed ID: 22393444
[TBL] [Abstract][Full Text] [Related]
18. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease).
Chauty A; Ardant MF; Adeye A; Euverte H; Guédénon A; Johnson C; Aubry J; Nuermberger E; Grosset J
Antimicrob Agents Chemother; 2007 Nov; 51(11):4029-35. PubMed ID: 17526760
[TBL] [Abstract][Full Text] [Related]
19. Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?
Converse PJ; Nuermberger EL; Almeida DV; Grosset JH
Future Microbiol; 2011 Oct; 6(10):1185-98. PubMed ID: 22004037
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.
Etuaful S; Carbonnelle B; Grosset J; Lucas S; Horsfield C; Phillips R; Evans M; Ofori-Adjei D; Klustse E; Owusu-Boateng J; Amedofu GK; Awuah P; Ampadu E; Amofah G; Asiedu K; Wansbrough-Jones M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3182-6. PubMed ID: 16048922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
